What is Ptc Therapeutics, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Ptc Therapeutics, Inc.'s reported free cash flow gives $267.96 per share. The share price was $62.67 on September 25, 2026, 77% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $164.85 | +163% |
| Base | 15.0% | 9.0% | $267.96 | +328% |
| Bull | 20.0% | 8.0% | $459.95 | +634% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $346.02 | $370.36 | $400.11 | $437.30 | $485.11 |
| 8.0% | $287.38 | $303.16 | $321.82 | $344.20 | $371.56 |
| 9.0% | $244.71 | $255.50 | $267.96 | $282.48 | $299.65 |
| 10.0% | $212.36 | $220.03 | $228.73 | $238.67 | $250.14 |
| 11.0% | $187.04 | $192.67 | $198.96 | $206.03 | $214.05 |
Where the presets come from
Base: years 1 to 5 grow at Ptc Therapeutics, Inc.'s revenue growth rate over the last 5 fiscal years (35.4% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions